[go: up one dir, main page]

BR0113234A - Polimorfos de um análogo de epotilona - Google Patents

Polimorfos de um análogo de epotilona

Info

Publication number
BR0113234A
BR0113234A BR0113234-2A BR0113234A BR0113234A BR 0113234 A BR0113234 A BR 0113234A BR 0113234 A BR0113234 A BR 0113234A BR 0113234 A BR0113234 A BR 0113234A
Authority
BR
Brazil
Prior art keywords
polymorphs
epothilone analog
analog
epothilone
methods
Prior art date
Application number
BR0113234-2A
Other languages
English (en)
Inventor
John D Dimarco
Jack Z Gougoutas
Imre M Vitez
Martha Davidovich
Michael Galella
Timothy M Malloy
Zhenrong Guo
Denis Favreau
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0113234(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0113234A publication Critical patent/BR0113234A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"POLIMORFOS DE UM ANáLOGO DE EPOTILONA". De acordo com a presente invenção são fornecidos dois polimorfos cristalinos, designados como Forma A e Forma B, respectivamente, assim como misturas destes, de um análogo de epotilona representado pela fórmula (I). Também são fornecidos métodos para formar os novos polimorfos, os métodos terapêuticos utilizando os mesmos e as formas de dosagem farmacêuticas contendo os mesmos.
BR0113234-2A 2000-08-16 2001-08-01 Polimorfos de um análogo de epotilona BR0113234A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22559000P 2000-08-16 2000-08-16
PCT/US2001/024540 WO2002014323A2 (en) 2000-08-16 2001-08-01 Polymorphs of an epothilone analog

Publications (1)

Publication Number Publication Date
BR0113234A true BR0113234A (pt) 2004-02-25

Family

ID=22845469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113234-2A BR0113234A (pt) 2000-08-16 2001-08-01 Polimorfos de um análogo de epotilona

Country Status (42)

Country Link
US (4) US6689802B2 (pt)
EP (1) EP1309597B1 (pt)
JP (1) JP5046467B2 (pt)
KR (1) KR100810342B1 (pt)
CN (1) CN1269821C (pt)
AR (1) AR034259A1 (pt)
AT (1) ATE366735T1 (pt)
AU (2) AU2001281082B2 (pt)
BG (1) BG66132B1 (pt)
BR (1) BR0113234A (pt)
CA (1) CA2418109C (pt)
CY (1) CY1107758T1 (pt)
CZ (1) CZ305523B6 (pt)
DE (1) DE60129334T2 (pt)
DK (1) DK1309597T3 (pt)
EE (1) EE05273B1 (pt)
ES (1) ES2288518T3 (pt)
GE (1) GEP20053495B (pt)
HK (1) HK1052010A1 (pt)
HR (1) HRP20030190B1 (pt)
HU (1) HU229314B1 (pt)
IL (2) IL153993A0 (pt)
IS (1) IS2845B (pt)
LT (1) LT5138B (pt)
LV (1) LV13032B (pt)
MX (1) MXPA03001431A (pt)
MY (1) MY134129A (pt)
NO (1) NO328500B1 (pt)
NZ (1) NZ523722A (pt)
PE (1) PE20020290A1 (pt)
PL (1) PL205628B1 (pt)
PT (1) PT1309597E (pt)
RO (1) RO123296B1 (pt)
RU (1) RU2272039C2 (pt)
SI (1) SI21100B (pt)
SK (1) SK287876B6 (pt)
TW (1) TWI320040B (pt)
UA (1) UA75365C2 (pt)
UY (1) UY26886A1 (pt)
WO (1) WO2002014323A2 (pt)
YU (1) YU12103A (pt)
ZA (1) ZA200300522B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
CA2434526C (en) * 2001-01-25 2011-11-01 Bristol Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
JP2004522774A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体を用いる耐性腫瘍の治療
MXPA03008135A (es) * 2001-03-14 2003-12-12 Bristol Myers Squibb Co Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas.
ATE375157T1 (de) * 2002-03-08 2007-10-15 Novartis Pharma Gmbh Kombinationspräparat aus epothilone derivate und imidazotetrazinone
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) * 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
TW200631609A (en) * 2004-11-18 2006-09-16 Bristol Myers Squibb Co Enteric coated bead comprising ixabepilone, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
US7693596B2 (en) 2005-12-14 2010-04-06 Dell Products L.P. System and method for configuring information handling system integrated circuits
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
CA2647565A1 (en) 2006-03-31 2007-10-18 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
KR101506466B1 (ko) 2006-05-16 2015-03-27 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
CN101506217B (zh) * 2006-08-16 2012-09-05 诺瓦提斯公司 埃坡霉素b的晶型及在药物组合物中的用途
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
US20110124690A1 (en) * 2007-02-23 2011-05-26 Danishefsky Samuel J Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20130086534A (ko) * 2010-06-01 2013-08-02 플러스 케미칼스, 에스.에이. 익사베필론의 고체 형태
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
EP2916872B1 (en) 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
CN103183681B (zh) * 2013-03-06 2016-01-13 浙江海正药业股份有限公司 伊沙匹隆的新晶型及其制备方法
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2021152107A1 (en) 2020-01-31 2021-08-05 Oncology Venture ApS Methods for predicting ixabepilone responsiveness in cancer patients
CN112457320A (zh) * 2020-11-30 2021-03-09 湖北宏中药业股份有限公司 一种提高伊沙匹隆合成反应速率的方法
CN112375085A (zh) * 2020-11-30 2021-02-19 湖北宏中药业股份有限公司 一种伊沙匹隆反应液的高收率高纯度处理方法
CN112409366A (zh) * 2020-11-30 2021-02-26 湖北宏中药业股份有限公司 一种伊沙匹隆二聚体的高收率制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1000809A (en) * 1960-11-02 1965-08-11 James Oakes & Company Riddings Pipe manufacture
DE2308418B2 (de) * 1972-06-21 1976-04-08 Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (pt) * 1973-01-29 1977-10-12
SE386365B (sv) * 1973-07-25 1976-08-09 L Brendling Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) * 1986-10-15 1988-04-28 Smc Corp 二重管およびその連続製造法
DE3927569A1 (de) * 1989-08-21 1991-02-28 Fritz Egger Gmbh Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) * 1989-12-01 1991-06-06 Baedje K H Meteor Gummiwerke Schlauch
WO1991011012A1 (en) * 1990-01-05 1991-07-25 Orscheln Co. Flexible synthetic plastic conduit
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4206096A1 (de) * 1992-02-27 1993-09-02 Wolf Woco & Co Franz J Koaxialrohr
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
PT903348E (pt) 1995-11-17 2002-11-29 Biotechnolog Forschung Mbh Gbf Derivados do epotilone e sua preparacao
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
IL129558A (en) 1996-11-18 2001-10-31 Biotechnolog Forschung Gmbh History of apothilone and pharmaceuticals and herbal preparations containing them
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DK0975638T3 (da) 1997-02-25 2002-11-18 Biotechnolog Forschung Gmbh Sidekædemodificerede epothiloner
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
CA2286610C (en) 1997-04-18 2007-03-13 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DE19833750A1 (de) 1997-07-16 1999-02-25 Schering Ag Thiazolderivate, Verfahren zur Herstellung und Verwendung
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
DE19747580A1 (de) 1997-10-28 1999-04-29 Siemens Ag Rangierfeld mit Anschlußleiste
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
WO1999039694A2 (en) 1998-02-05 1999-08-12 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19807505A1 (de) 1998-02-21 1999-08-26 Roland Man Druckmasch Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
AU5325699A (en) * 1998-08-12 2000-03-06 Proteus Inc. Ribbed core dual wall structure
PT1140944E (pt) 1998-12-22 2004-01-30 Novartis Pharma Gmbh Derivados de epotilona e sua utilizacao como agentes antitumorais
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6605559B1 (en) * 1999-09-29 2003-08-12 Daihatsu Motor Co., Ltd. Dimethyl ether reforming catalyst
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
IL156580A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
CN100341505C (zh) 2001-01-25 2007-10-10 布里斯托尔-迈尔斯斯奎布公司 用于治疗癌症的埃博霉素类似物的给药方法
US9317043B2 (en) 2013-12-19 2016-04-19 Google Inc. Path based power generation control for an aerial vehicle

Also Published As

Publication number Publication date
SK1342003A3 (en) 2003-09-11
JP5046467B2 (ja) 2012-10-10
HUP0300826A2 (hu) 2003-09-29
JP2004506638A (ja) 2004-03-04
BG66132B1 (bg) 2011-06-30
SI21100A (sl) 2003-06-30
AU2001281082B2 (en) 2007-01-04
US6689802B2 (en) 2004-02-10
UY26886A1 (es) 2002-03-22
RO123296B1 (ro) 2011-06-30
US6982276B2 (en) 2006-01-03
NZ523722A (en) 2005-04-29
ATE366735T1 (de) 2007-08-15
RU2272039C2 (ru) 2006-03-20
GEP20053495B (en) 2005-04-25
US7153879B2 (en) 2006-12-26
HU229314B1 (en) 2013-10-28
EP1309597A2 (en) 2003-05-14
CZ305523B6 (cs) 2015-11-18
HRP20030190A2 (en) 2003-04-30
HUP0300826A3 (en) 2005-05-30
CN1269821C (zh) 2006-08-16
PE20020290A1 (es) 2002-04-03
LT2003017A (en) 2004-03-25
KR100810342B1 (ko) 2008-03-07
CN1468243A (zh) 2004-01-14
WO2002014323A3 (en) 2002-05-02
USRE39251E1 (en) 2006-08-29
SI21100B (sl) 2009-12-31
CA2418109A1 (en) 2002-02-21
DK1309597T3 (da) 2007-10-22
HRP20030190B1 (en) 2011-07-31
PL205628B1 (pl) 2010-05-31
IS6714A (is) 2003-02-11
YU12103A (sh) 2006-08-17
NO328500B1 (no) 2010-03-01
IL153993A (en) 2009-07-20
DE60129334T2 (de) 2008-04-03
EE200300063A (et) 2004-12-15
CZ2003418A3 (cs) 2004-01-14
NO20030707D0 (no) 2003-02-14
US20020188014A1 (en) 2002-12-12
LT5138B (lt) 2004-06-25
HK1052010A1 (en) 2003-08-29
MY134129A (en) 2007-11-30
TWI320040B (en) 2010-02-01
SK287876B6 (sk) 2012-02-03
DE60129334D1 (en) 2007-08-23
US20040157897A1 (en) 2004-08-12
EE05273B1 (et) 2010-02-15
ZA200300522B (en) 2004-04-20
AU8108201A (en) 2002-02-25
KR20030022411A (ko) 2003-03-15
CA2418109C (en) 2011-09-27
ES2288518T3 (es) 2008-01-16
CY1107758T1 (el) 2013-06-19
IL153993A0 (en) 2003-07-31
NO20030707L (no) 2003-04-15
PT1309597E (pt) 2007-08-22
MXPA03001431A (es) 2004-05-04
PL365610A1 (en) 2005-01-10
UA75365C2 (en) 2006-04-17
LV13032B (en) 2003-12-20
AR034259A1 (es) 2004-02-18
US20060063815A1 (en) 2006-03-23
BG107467A (bg) 2003-09-30
IS2845B (is) 2013-08-15
WO2002014323A2 (en) 2002-02-21
EP1309597B1 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
BR0113234A (pt) Polimorfos de um análogo de epotilona
BR0108678A (pt) Novos compostos
SE0200979D0 (sv) New compounds
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BRPI0409136A (pt) composto heteroaromático pentacìclico e uso medicinal do mesmo
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
PA8547701A1 (es) Nucleosidos 4 substituidos.
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
UY28374A1 (es) Agentes terapéuticos
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
DK1248605T3 (da) Hidtil ukendte sertralinhydrochloridpolymorfer, processer til deres fremstilling, sammensætninger indeholdende dem og fremgangsmåder til deres anvendelse
SE0302192D0 (sv) Novel compounds
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
SE0100569D0 (sv) New compounds
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
BRPI0410044B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
BRPI0416745A (pt) novos compostos
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne
ECSP034929A (es) Pirimidinas inhibidoras de cdk, su preparación y uso como medicamento
BRPI0410056A (pt) intermediários de imidazopiridina
SE0401716D0 (sv) New compounds
BR0307708A (pt) Compostos tricìclicos de n-acila

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. C07D 491/00, A61P 35/00

Ipc: C07D 491/00 (2011.01), A61P 35/00 (2011.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25B Requested transfer of rights rejected

Owner name: BRISTOL-MYERS SQUIBB COMPANY (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]